Test your brains with the Herald's afternoon quiz. Be sure to check back on nzherald.co.nz for the morning quiz tomorrow. To challenge yourself with more quizzes, CLICK HERE.

The rabbi claimed that conversion therapy is a necessary procedure between ages 13 and 15 in order to rid people of their homosexual tendencies.

LAHORE: Researchers at the University of Health Sciences Saturday launched a clinical trial to assess blood plasma therapy for Covid-19 treatment.On the appeal of UHS Vice Chancellor Prof Javed...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Researchers led by Albert-László Barabási used network-based models to discover existing drugs that might take on COVID-19

An Edmonton family is expressing frustration because their 12-year-old daughter, who has a rare disorder, cannot access the horse therapy she needs.

The pandemic has thrown publishing and booksellers into crisis – and left customers struggling to obtain books when they most want them. But some in the industry sense an opportunity to drag it into the 21st century

On 18 March, Emma Corfield-Walters received the news that for the second year running, her shop, Book-ish, in Crickhowell in the Brecon Beacons, had landed the title for Wales in the regional round of the independent bookshop of the year award. Corfield-Walters has run Book-ish for 10 years. It has 16 staff and a cafe, is the base for a literary festival that she also organises, and is credited with having played a major part in the regeneration of Crickhowell’s award-winning high street. Above all, it is a highly successful business: 2019 was a record year. The fact that it would now again be a contender for the overall prize – to be announced in June at the British book awards – was for Corfield-Walters a hard-earned affirmation of a decade’s passion and work.

But she was hardly celebrating. Britain was then five days from lockdown. “It was surreal,” she says. “We’d won best bookshop in Wales, yet I wasn’t sure for how much longer I’d have a shop that people could visit. It was like that scene in Star Wars when the walls are moving in, and the room’s getting smaller and smaller. The goalposts were shifting every day. At first, we thought: OK, we’ll buy hand sanitiser! But by the weekend, it was clear the shop would have to close.” Her first thought was for her staff, who are “like family” to her; the government’s subsequent announcement of its furlough scheme came as a huge relief. But there was also the question of her stock, and how she might keep selling it. Suddenly, the Book-ish website, hitherto used only to sell event tickets and signed copies, came into its own: “On the Saturday before lockdown began, we managed to get all 6,000 titles from the shop on to our website.”

Producer Karim Morani's daughter Zoa Morani donated her blood for plasmatherapy trials for COVID-19 treatment at Mumbai's Nair hospital. Zoa, who has recently recovered from coronavirus along with her father Karim Morani and sister Shaza Morani, took to Instagram to inform everyone about her blood donation. She also mentioned that any person who has recovered from COVID-19, can take part in the cause.

"Donated my blood today for the #plasmatherapy trials at #nairhospital.. it was fascinating!!! Always a silver lining i suppose... the team there was so enthusiastic and careful. There was a general physician on standby just incase of emergency and the equipment brand new and safe!!! All #Covid19 recovered people can be a part of this trial, to help others covid patients recover! Thank you Dr Jayanti Shastri and Dr Ramesh Waghmare for taking such good care of me.. hope this works #covidrecovery #IndiaFightsCorona," shared Zoa on Instagram on Saturday evening.

 

 

 

View this post on Instagram

Donated my blood today for the #plasmatherapy trials at #nairhospital .. it was fascinating !!! Always a silver lining i suppose ... the team there was so enthusiastic and careful. There was a general physician on standby just incase of emergency and the equipment brand new and safe !!! All #Covid19 recovered people can be a part of this trial , to help others covid patients recover ! Thank you Dr Jayanti Shastri and Dr Ramesh Waghmare for taking such good care of me .. hope this works 🤲🏽🤲🏽🤲🏽🤲🏽🤲🏽🤲🏽 #covidrecovery #IndiaFightsCorona They even gave me a certificate and 500 rs , Wont lie , i felt super cool today ☺ï¸Â

A post shared by Zoa💫 (@zoamorani) onMay 9, 2020 at 6:22am PDT

Zoa shared photographs from the hospital clicked during and after her blood donation.

She also informed in her post that her blood donation has been acknowledged with a certificate and a Rs-500 remittance by the hospital and she feels "super cool" about it!

Catch up on all the latest entertainment news and gossip here. Also, download the new mid-day Android and iOS apps.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

Dogs are miracles with paws. A dog named Deuce is perhaps the best example of this. He is a three-year-old who had his legs amputated because they were infected. However, he has managed to beat the odds and is able to walk on his two right legs.

"Although, he only has legs on the right side, he is very strong and stable and can walk and run just as steadily as any other dog with four legs," said Domenick Scudera, his pet parent and a theatre professor at Ursinus College in Pennsylvania, to SWNS. Scudera found him in a ditch and rescued him. Not only is Deuce's walking ability a wonder, the sweet pup is a miracle worker who travels to hospitals to visit children as a therapy dog.

Deuce with Lucky

The professor also cares for a couple of other two-legged dogs named Cyrus and Lucky. All three are therapy dogs who inspire others, leading by example. "They have completely changed my life for the better. They mean the world to me," added Scudera. Their story seems to have resonated with others as the three dogs have their own Instagram page with nearly 50,000 followers.

The desi voice America loves

A 14-year-old singing brainiac, who started college at the age of seven, has been accepted into eight Californian varsities

An Indian-American teen prodigy, Tiara Abraham, who graduated from high school at the age of 13, has now been accepted into the music programmes at eight different Californian universities. Abraham became a member of MENSA, the high-IQ society, at the tender age of four and took her first college class at the age of seven. Her ambition is to become an opera performer. "I don't know, it's just something that's in me. I'm just really passionate about it. Singing makes me feel happy, it's my passion," she said to KXTV. Her mother Taji Abraham said, "We are super proud. It's super competitive with these vocal majors."

The 14-year-old is currently a full-time student at American River College. She is trying to choose between the University of Southern California, the University of the Pacific and six others.

Bhangra in Britain

Pic/@100stringsingh, Instagram

Singer and actor Diljit Dosanjh shared a heartwarming video on Twitter, which showed people in London dancing to his song Veervaar. It was originally posted by Twitter user @shergillj99. It features him doing the bhangra and his white neighbours at the other end of the street following his lead.

Grim reaper says stay safe

Pic/@DWUhlfelderLaw, Twitter

Beaches in Florida were recently reopened to the public. People who visited them hoping to catch some sun were shocked, as they spotted a scythe-wielding Grim Reaper at these beaches. Daniel Uhlfelder has been dressing up as the symbol of death and haunting these beaches to protest their opening during the Coronavirus pandemic. He wants people to stay indoors."

Lady drinks smoothies with sperm to stay fit

Pic/Tracy Kiss, Facebook

Tracy Kiss, a UK-based personal trainer, told Metro that she hasn't fallen sick for the past three years because of her smoothies, which contain sperm. She takes three shots a week and makes the smoothies using donations from her boyfriend. The 32-year-old mother of two said, "I found a free and vegan-friendly alternative method to boost the body's immune system.

Elon Musk names his baby X Æ A-12

What's in a name? If you think nothing, you might change your mind as you hear about Tesla CEO Elon Musk naming his baby boy X Æ A-12 Musk. His partner, Grimes, came up with the outlandish name. "...the AE is, like, pronounced Ash," said Musk on comedian Joe Rogan's podcast.

Care to wear a shirt made of waste linen?

Pic/Archivist Studio, Facebook

Archivist Studio, a German clothing brand, has been repurposing linen discarded by luxury hotels into designer shirts. The idea is the brainchild of designer duo Eugenie Haitsma and Johannes Offerhaus, who learned that bed linen get thrown out for the smallest of defects.

A table for one, please

A Swedish restaurant is letting customers enjoy the fine dining experience. The creators of Bord för en (table for one), Linda Karlsson and Rasmus Persson, have placed a wooden table and a chair in the middle of a barren field. Customers have to serve themselves from a picnic basket placed near the table. The guest can pay what they want for the meal. Pics/@bordforen, Facebook

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"A lovely thing about Christmas is that it's compulsory, like a thunderstorm, and we all go through it together." - Ga

Chromotherapy, one of the newly developed branches of alternative medicine, seems to have gained an increasing acceptan

The OECD LEED Trento Centre is working with Italy and the Autonomous Province of Trento to strengthen capacities to develop and implement integrated strategies targeted at improving the quality of life and well-being of people and reversing demographic trends in ‘inner areas’ (sparsely populated areas and stranded communities isolated from large and medium-sized urban centres).

The OECD LEED Trento Centre is working with Italy and the Autonomous Province of Trento to strengthen capacities to develop and implement integrated strategies targeted at improving the quality of life and well-being of people and reversing demographic trends in ‘inner areas’ (sparsely populated areas and stranded communities isolated from large and medium-sized urban centres).

1. Zoa Morani Donates Blood For Covid-19 Plasmatherapy, Says "It Felt Super Cool"  News18
2. Zoa Morani donates blood for Covid-19 plasmatherapy: ‘They even gave me a certificate and Rs 500. Wont...  Hindustan Times
3. COVID-19 survivor Zoa Morani donates blood for plasma therapy  Jimmys Post
4. Karim Moranis daughter Zoa donates blood for plasma therapy trials  Geo News
5. Zoa Morani urges all Covid-19 recovered people to donate blood for plasma therapy trials  The News International
6. View Full coverage on Google News

The new wave of high-spec suncreams are kind to skin - and the ocean

Can you imagine arguing with your husband in the car, and when you get out to go to Starbucks, you're still pi**ed off with each other? Now imagine doing that when you're famous.'

The doctor, who was on ventilator since the last 14 days, died on Saturday evening following heart attack.

Actress Zoa Morani, who along with sister Shaza and father, film producer Karim Morani recovered from Covid-19 in April donated her blood for plasmatherapy.

Lucknow, May 09: The first patient to receive plasma therapy as an experimental treatment for coronavirus infection in Uttar Pradesh died following a heart attack on Saturday. The patient, a 58-year-old doctor, was admitted at the King George’s Medical University

Actress Zoa Morani, who had tested positive for Coronavirus in early April, has donated her blood for plasmatherapy trials, at the Nair Hospital in Mumbai on Saturday. Zoa took to her Instagram handle to share pictures where she can be seen

Actress Zoa Morani, who had tested positive for Coronavirus in early April, has donated her blood for plasmatherapy trials, at the Nair Hospital in Mumbai on Saturday. Zoa took to her Instagram handle to share pictures where she can be seen

Zoa shared photographs from the hospital clicked during and after her blood donation.

Archives, Room Use Only - TK5742.S63 1917

Zoa Morani donates blood in Mumbai for plasma therapy to help those af...

Existing BBCI patients to get therapy

The doctor, who was on ventilator since the last 14 days, died on Saturday evening following a heart attack, KGMU Vice Chancellor M L B Bhatt said

Producer Karim Morani's daughter Zoa Morani donated her blood for plasmatherapy trials for COVID-19 treatment at Mumbai's Nair hospital today.

On Aug, 31, the Smithsonian’s National Zoo welcomed this year’s second litter of African lion (Panthera leo) cubs. Five-year-old Shera (shown at right) gave birth […]

The post Shera, a 5-year-old lioness at the National Zoological Park appeared first on Smithsonian Insider.

The studio arts program at California Lutheran University in Thousand Oaks, Calif., includes courses in painting. ; Credit: Photo courtesy of Cal Lutheran/Brian Stethem

California Lutheran University in Thousand Oaks has taken the first steps toward building a new, art center with a commitment of at least $8 million in contributions and matching funds.

Over the weekend, the university's board of regents voted to spend $300,0o0 on design and planning for the new project. The complex will include offices and art studios in about 25,000 to 30,000 square feet of space.

RELATED: Top 10 arts education stories for 2014

The center will be the new home for the school's art department, which is currently spread out across the campus. 

"The facilities that they're in now are really not optimal," said Karin Grennan, the media relations manager for the university. 

The school offers instruction in studio arts, design and commercial art, digital art and art history. 

Grennan said the new project will add to the university's recent art initiatives: in 2012, the faculty members launched an art conference that's attracted international interest. Two conferences have been held so far and the next one will take place in November. The university is also raising funds to build a new performing art center on campus. 

Art collector and real estate developer William Rolland pledged up to $4 million toward the art center project, an amount the university will match. 

Rolland has previously donated money to the university, including contributions for the football stadium and art gallery. Rolland spent several decades as a real estate developer in Ventura County, and once lived in Thousand Oaks. 

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions, says a new report by the National Academies of Sciences, Engineering, and Medicine.

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.

read more

The expression dog is man's best friend might have more weight in the case of first-year university students suffering from homesickness, according to a new UBC study.

read more

Cranial sacral therapy also known as craniosacral therapy is a gentle technique that releases tensions deep inside the body to reduce pain and dysfunction.

The longing you feel to get away is ancient, says writer Clemens Arvay, a desire to interact with nature and leave behind the material world.

Carrie Underwood gives her dog water therapy to deal with paralysis in his back legs.

Homemade aromatherapy shower squares can help relieve stress and even allergies. Here's how to make them yourself.